What is the Fredun Pharmaceuticals Ltd share price today?

The share price of NSE:FREDUN-EQ on 07 Sep 2026 (as of 10:59:19 IST) is ₹1458.50.

What is the NSE:FREDUN-EQ 52 week high low price?

Over the past 52 weeks (as of 07 Sep 2026), the NSE:FREDUN-EQ 52 week high low range shows a high of ₹1590.00 and a low of ₹1400.00.

What is the Fredun Pharmaceuticals Ltd market cap?

As on 07 Sep 2026, Fredun Pharmaceuticals Ltd market cap is ₹2437.88 Cr.

What is the shareholding pattern of Fredun Pharmaceuticals Ltd Stock?

The shareholding pattern of Fredun Pharmaceuticals Ltd, as of last reported-on 30 Jun 2026 is: Promoters: 44.57% Foreign Institutional Investors (FII): 1.06% Domestic Institutional Investors (DII): 2.94% Mutual Funds: 0% Retail & Others: 51.43% This demonstrates an outstanding distribution of ownership.

What are the PE and PB ratios of Fredun Pharmaceuticals Ltd?

The Price-to-Earnings (PE) ratio of Fredun Pharmaceuticals Ltd is 55.63, and the Price-to-Book (PB) ratio is 3.46, as on 07 Sep 2026.

Fredun Pharmaceuticals Share Price

1376.60-18.75 (-1.34%)

+236.14% past 1 Year

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

1 Day

-1.34%

1 Week

+5.42%

1 Month

-5.04%

3 Month

+53.55%

6 Month

+143.83%

YTD

+161.66%

1 Year

+236.14%

5 Year

+582.39%

10 Year

Max

+725.96%

YTD

10Y

MAX

Prices are delayed by 1 hour. Login or Sign Up for live updates.Prices are delayed by 1 hour. Login or Sign Up for live updates.

Price Analysis

1 Day

1 Week

1 Month

3 Months

6 Months

1 Year

Low

1351.55

1300.00

1193.35

823.93

555.73

403.72

High

1392.60

1411.25

1540.25

1600.00

About

Fredun Pharmaceuticals Limited is engaged in manufacturing of pharmaceutical products. The company is trusted by customers across Africa, Southeast Asia, Commonwealth of Independent States (CIS) countries and Latin America. The Read more

Pharmaceuticals & Drugs

Smallcap

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats

1. Premium insight available after login

2. Sign in to view full SWOT analysis

3. Unlock strengths, weaknesses, opportunities & threats

QVT

Quality

0/100-

Valuation

0/100-

Technical

0/100-

Peer Stocks

1 week

1 month

1 year

Name

SUNPHARMA-ANSE

DIVISLAB-ANSE

TORNTPHARM-ANSE

ZYDUSLIFE-ANSE

CIPLA-ANSE

LAURUSLABS-ANSE

MANKIND-ANSE

DRREDDY-ANSE

AUROPHARMA-ANSE

LUPIN-ANSE

FREDUN-BNSE

LTP

1W Low

1W High

Market cap (₹)

1853+17.5 (0.95%)

1835.50

1890.40

4,47,476Cr

9613+246 (2.63%)

9305.95

9739.85

2,54,764Cr

4935+130.75 (2.72%)

4864.80

5010

1,89,423Cr

1180+27 (2.34%)

1152

1191

1,16,658Cr

1404+32.55 (2.37%)

1364

1418.70

1,11,484Cr

2026.25+71 (3.63%)

1964.50

2054.55

1,09,943Cr

2475+157 (6.77%)

2302.30

2503.20

1,01,712Cr

1200.4+29.3 (2.50%)

1186.20

1221.60

1,01,005Cr

1720-15 (-0.86%)

1690

1739.60

99,253Cr

2098-46.7 (-2.18%)

2084.50

2129.85

96,031Cr

1376.6+70.75 (5.42%)

1300

1411.25

2,358Cr

Fredun Pharmaceuticals Share Price

1376.60-18.75 (-1.34%)

+236.14% past 1 Year

Financial overview

Compounded Sales Growth

10 years-

5 years-

3 years-

Last year40%

Compounded Profit Growth

10 years-

5 years-

3 years-

Last year65%

Stock Price CAGR

10 years-

5 years47%

3 years68%

1 year241%

Return on Equity

10 years15%

5 years15%

3 years15%

Last year16%

CAGR%

Sales

Profits

Returns

ROE

10Y	5Y	3Y	TTM
-	-	-	40%
-	-	-	65%
-	47%	68%	241%
15%	15%	15%	16%

Peer Comparison

Symbol

SUNPHARMA-A

DIVISLAB-A

TORNTPHARM-A

ZYDUSLIFE-A

CIPLA-A

LAURUSLABS-A

MANKIND-A

DRREDDY-A

AUROPHARMA-A

LUPIN-A

FREDUN-B

Price	M.Cap (₹)	PE Ratio	EPS (₹)	EV/EBITDA	Annual PAT
1,853	₹447476 Cr	37	12.07	62.82	₹11479 Cr
9,613	₹254764 Cr	87.1	34.04	128.41	₹2568 Cr
4,935	₹189423 Cr	86.85	16.72	97.06	₹2163 Cr
1,180	₹116658 Cr	25.85	9.42	62.53	₹5040 Cr
1,404	₹111484 Cr	33.08	9.77	57.87	₹3879 Cr
2,026.25	₹109943 Cr	100.55	6.8	29.25	₹889 Cr
2,475	₹101712 Cr	49.79	13.75	71.08	₹1913 Cr
1,200.4	₹101005 Cr	31.35	5.32	63.99	₹4196 Cr
1,720	₹99253 Cr	26.73	17.95	96.84	₹3505 Cr
2,098	₹96031 Cr	17.37	30.95	154.35	₹5333 Cr
1,376.6	₹2358 Cr	53.81	7.94	32.08	₹33 Cr

Profit & Loss

Consolidated

Standalone

Quarterly

Yearly

₹

Balance Sheet

Consolidated

Standalone

₹

Name

Equity And Liabilities

Share Capital

Share Warrants & Outstandings

Total Reserves

Reserve excluding Revaluation Reserve

Shareholder's Funds

Minority Interest

Secured Loans

Deferred Tax Assets / Liabilities

Other Long Term Liabilities

Long Term Provisions

Total Non-Current Liabilities

Current Liabilities

Trade Payables

Other Current Liabilities

Short Term Borrowings

Short Term Provisions

Total Current Liabilities

Total Liabilities

Total Debt

Assets

Gross Block

Less Accumulated Depreciation

Net Block

Non Current Investments

Long Term Investment

Long Term Loans & Advances

Other Non Current Assets

Total Non-Current Assets

Current Assets Loans & Advances

Inventories

Sundry Debtors

Cash and Bank

Other Current Assets

Short Term Loans and Advances

Total Current Assets

Net Current Assets (Including Current Investments)

Total Assets

Book Value

Adjusted Book Value

Mar 2026	Mar 2025
—	—
₹5 Cr	₹5 Cr
₹14 Cr	₹0
₹259 Cr	₹137 Cr
₹259 Cr	₹137 Cr
₹278 Cr	₹141 Cr
-₹1,000	₹0
₹56 Cr	₹10 Cr
₹7 Cr	₹4 Cr
₹0	₹2,000
₹4 Cr	₹4 Cr
₹67 Cr	₹18 Cr
—	—
₹88 Cr	₹145 Cr
₹53 Cr	₹26 Cr
₹146 Cr	₹151 Cr
₹10 Cr	₹7 Cr
₹297 Cr	₹328 Cr
₹642 Cr	₹487 Cr
₹222 Cr	₹167 Cr
—	—
₹148 Cr	₹75 Cr
₹30 Cr	₹22 Cr
₹118 Cr	₹53 Cr
₹2 Cr	₹2 Cr
₹2 Cr	₹2 Cr
₹12 Cr	₹5 Cr
₹11 Cr	₹76 L
₹144 Cr	₹60 Cr
—	—
₹270 Cr	₹240 Cr
₹93 Cr	₹177 Cr
₹65 Cr	₹5 Cr
₹7 Cr	₹3 Cr
₹64 Cr	₹2 Cr
₹498 Cr	₹427 Cr
₹201 Cr	₹99 Cr
₹642 Cr	₹487 Cr
₹483	₹299
₹483	₹299

Cash Flow

Consolidated

Standalone

₹

Name

Profit Before Tax

Adjustment

Changes In working Capital

Cash Flow after changes in Working Capital

Cash Flow from Operating Activities

Cash Flow from Investing Activities

Cash Flow from Financing Activitie

Net Cash Inflow / Outflow

Opening Cash & Cash Equivalents

Closing Cash & Cash Equivalent

Mar 2026	Mar 2025
₹35 Cr	₹27 Cr
₹46 Cr	₹28 Cr
-₹69 Cr	-₹72 Cr
₹12 Cr	-₹17 Cr
₹12 Cr	-₹17 Cr
-₹74 Cr	-₹6 Cr
₹121 Cr	₹27 Cr
₹60 Cr	₹4 Cr
₹5 Cr	₹2 Cr
₹65 Cr	₹5 Cr

Fundamental Ratios

Consolidated

Standalone

Fredun Pharmaceuticals Share Price

1376.60-18.75 (-1.34%)

+236.14% past 1 Year

Shareholding summary

Promoters

44.57%

FII

1.06%

DII

2.94%

Others

51.43%

Promoters

FII

DII

Others

Quarterly

Yearly

Shareholding Pattern

Quarterly

Yearly

Name

Promoters

FII

DII - Others

DII - MFs

Retail & Others

Jun 2026	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
44.57%	44.17%	43.06%	48.93%	48.93%	48.93%
1.06%	1.06%	0.46%	0.01%	0.00%	0.00%
2.94%	2.83%	3.48%	1.61%	1.59%	1.59%
0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
51.43%	51.94%	53.00%	49.45%	49.48%	49.48%

Bulk & block deals

Name

Anand Jhingan

Ashok Jhingan

Zaheer .

Kamal Kumar Jalan Sec. Pvt. Ltd

Surinder Gurmukh Dhaul

Zaheer .

Kamal Kumar Jalan Sec. Pvt. Ltd

Surinder Gurmukh Dhaul

Madhubala Paresh Trivedi

Deal Date	Action	Deal Value	Deal Price	Qty Traded	Deal Type	%Stake Traded	Exchange
14 Sep 2021	Sell	1.05 Cr	₹422.48	24.76 K	Bulk	0.173315	BSE
14 Sep 2021	Sell	1.06 Cr	₹443.07	24 K	Bulk	0.168008	BSE
01 Jul 2020	Purchase	2.08 Cr	₹186.01	1.12 L	Bulk	0.784214	BSE
01 Jul 2020	Purchase	62.61 L	₹184.83	33.87 K	Bulk	0.237116	BSE
01 Jul 2020	Purchase	45.65 L	₹183.48	24.88 K	Bulk	0.174176	BSE
01 Jul 2020	Sell	2.05 Cr	₹183.28	1.12 L	Bulk	0.784214	BSE
01 Jul 2020	Sell	63.11 L	₹187.30	33.70 K	Bulk	0.235891	BSE
01 Jul 2020	Sell	46.33 L	₹186.19	24.88 K	Bulk	0.174176	BSE
15 Jan 2018	Sell	21.98 L	₹142.70	15.40 K	Bulk	0.107805	BSE

Insider trading & SAST

Client name

Fredun Nariman Medhora & Others

Daulat Medhora

Fredun Medhora

Daulat Medhora

Fredun Medhora

Daulat Medhora

Nariman Medhora

Daulat Medhora

Reported on	Client category	Action	%Stake traded	Holding % post deal	Deal value	Deal price	Qty traded	Deal period	Deal mode	Post transaction holding	Insider/SAST	Regulation type	Security type
15 May 2026	Promoter	Acquisition	0.73	44.57	0	—	40 K	09 Apr 2026	Conv. of Warrants	24,57,053	SAST	29(2)	—
13 Apr 2026	Promoter & Director	Acquisition	0.840036	26.32	5 Cr	₹1,250	40 K	09 Apr 2026	Conversion of security	14,50,898	Insider Trading	—	Equity Shares
26 Mar 2026	Promoter & Director	Acquisition	2.259102	5.23	13.33 Cr	₹1,250	1.07 L	25 Mar 2026	Conversion of security	2,86,340	Insider Trading	—	Equity Shares
22 Sep 2023	Promoter & Director	Acquisition	0.410654	3.82	1.90 Cr	₹996.20	19.07 K	22 Sep 2022	Allotment	1,79,172	Insider Trading	—	Equity Shares
25 Aug 2023	Promoter & Director	Acquisition	0.389036	30.38	1.80 Cr	₹996.20	18.07 K	23 Aug 2023	Allotment	14,10,898	Insider Trading	—	Equity Shares
18 Oct 2022	Promoter & Director	Acquisition	0.428324	0.4	1.90 Cr	₹996.20	19.07 K	15 Oct 2022	Allotment	19,072	Insider Trading	—	Warrants
18 Oct 2022	Promoter & Director	Acquisition	0.405776	0.38	1.80 Cr	₹996.20	18.07 K	15 Oct 2022	Allotment	18,068	Insider Trading	—	Warrants
25 Nov 2021	Promoter & Director	Acquisition	3.622293	16.24	6.10 Cr	₹422.10	1.45 L	23 Nov 2021	Allotment	7,19,815	Insider Trading	—	Equity Shares
25 Nov 2021	Promoter & Director	Acquisition	1.306397	31.42	2.20 Cr	₹422.10	52.12 K	23 Nov 2021	Allotment	13,92,830	Insider Trading	—	Equity Shares
22 Nov 2021	Promoter & Director	Acquisition	1.308652	1.17	2.20 Cr	₹421.37	52.21 K	17 Nov 2021	Allotment	52,210	Insider Trading	—	Warrants

Fredun Pharmaceuticals Share Price

1376.60-18.75 (-1.34%)

+236.14% past 1 Year

Corporate Actions

Date

Type

Details

2026-07-16

Bonus

2:1

2026-06-23

Dividend

0.7

2025-09-23

Dividend

0.7

2024-09-23

Dividend

0.7

2023-09-22

Dividend

0.7

Company details

Registered office

11th Floor, Tower A Urmi Estate 95, Ganpatrao Kadam Marg Lower Parel (West) Mumbai Maharashtra PIN: 400013 Tel No: 022-40318111 Fax No: 022-40318133 Email: [email protected] Internet: www.fredungroup.com

Registrars

Gala No 9, Shiv Shakti, Industrial EstateSitaram Mill Compound, J R Boricha Marg Gala No 9 Shiv Shakti, Industrial Estate,Sitaram Mill Comp. J R Boricha Marg, Lower Parel [E] PIN: Tel No: +91 22 4134 3255/ +91 22 4134 3256 Fax No: NULL Email: [email protected] Internet: www.purvashare.com

Management

Daulat Medhora, Chairperson & Joint Managing Director

Fredun Medhora, Managing Director & Chief Financial Officer

Pooja Narendra Sanghavi, Non Executive Independent Director

Anshu Agarwal, Non Executive Independent Director

Sonal Dharmin Desai, Non Executive Independent Director

Daisy Cyril Dsouz, Non Executive Independent Director

Details

BSE 539730

NSE FREDUN

ISIN INE194R01017

Fredun Pharmaceuticals Share Price

Price Analysis

Share Price Live Stats

Share Market Cap & Key Ratios Overview

About

Stock Analysis (SWOT)

QVT

Peer Stocks

Fredun Pharmaceuticals Share Price

Fredun Pharmaceuticals Share Price

Financial overview

Compounded Sales Growth

Compounded Profit Growth

Stock Price CAGR

Return on Equity

Peer Comparison

Profit & Loss

Balance Sheet

Cash Flow

Fundamental Ratios

Fredun Pharmaceuticals Share Price

Fredun Pharmaceuticals Share Price

Oscillators

Moving averages

Fredun Pharmaceuticals Share Price

Shareholding summary

Shareholding Pattern

Bulk & block deals

Insider trading & SAST

Fredun Pharmaceuticals Share Price

Corporate Actions

Company details

Fredun Pharmaceuticals Share Price

Corporate filings & documents

Announcements

Annual reports

Concalls & investor presentations

Fredun Pharmaceuticals Share Price

News

Fredun Pharma Targets Rs 40 Crore Revenue By FY27 And Rs 56 Crore By FY28

Fredun Pharmaceuticals Acquires Stake In Goodman Vetcare For Rs 300 Crores

Fredun Pharma acquires Furlicks brand, enters pet wellness segment aggressively

Fredun Pharmaceuticals informs about conference call

Fredun Pharma - Quaterly Results

Fredun Pharma reports Profit after tax of 11.06 Crores, in the March 2026 quarter

Fredun Pharmaceuticals gains on launching Hormone Range Products

Fredun Pharmaceuticals launches Hormone Range Products

Fredun Pharmaceuticals moves up on launching cellular longevity dedicated platform ‘Daulcel’

Fredun Pharmaceuticals launches cellular longevity dedicated platform ‘Daulcel’

Fredun Pharmaceuticals submits board meeting intimation

Fredun Pharmaceuticals establishes new manufacturing facility in Palghar

Fredun Pharma - Quaterly Results

Fredun Pharma reports Profit after tax of 10.48 Crores, in the December 2025 quarter

Fredun Pharmaceuticals informs about appointment of company secretary

Fredun Pharma reports Profit after tax of 9.73 Crores, in the September 2025 quarter

Fredun Pharmaceuticals zooms on launching ‘Snacky Jain’

Fredun Pharmaceuticals launches ‘Snacky Jain’

Fredun Pharmaceuticals informs about certificate

Fredun Pharmaceuticals moves up on acquiring Wagr

Fredun Pharmaceuticals Ltd Share Price Today

Fredun Pharmaceuticals Quick Links

Other Stocks

Calculators

Brokerage Calculator

Stock Average Calculator

MTF Calculator

Margin Calculator

Span Margin Calculator